SpecOpt
An agent framework for target-specific optimization of drug molecules. It integrates molecular docking, LLM-driven structural modification suggestions, and multi-stage screening mechanisms to improve a molecule's binding preference for a target while preserving the original drug scaffold.
Timeline (last 90 days)
SpecOpt is defined as a molecular design task: performing constrained structural modifications to existing compounds to make them preferentially bind to an intended target over known off-target proteins, while retaining their original structural characteristics and drug-like properties.
The SpecOpt framework focuses on improving existing well-characterized drugs rather than generating entirely new selective molecules.
The researchers constructed a benchmark for evaluating specificity optimization tasks based on compound-target interaction data from ChEMBL, in which intended targets are identified through drug mechanism annotations and off-target proteins are determined through measured activity data.
SpecOpt provides differential interaction information to a large language model, which then proposes targeted structural modification suggestions.
Candidate molecules generated by SpecOpt are accepted only if they simultaneously satisfy three criteria: molecular similarity, ADMET properties, and target-versus-off-target docking selectivity.
On a test set of 915 compounds, SpecOpt improved the target-off-target binding gap for 84.8% of the compounds.
SpecOpt improved the average binding gap from -0.72 kcal/mol to +0.47 kcal/mol.
The average Tanimoto similarity between SpecOpt-optimized molecules and their starting compounds was maintained at 0.72.
In ablation experiments, when specific residue identities were replaced with binary contact indicators, the improvement effects completely disappeared for all 29 ablation compounds.
Ablation studies indicate that residue-specific contact information is the key signal driving specificity optimization performance, and merely knowing that contacts exist is insufficient for making meaningful structural judgments.
All Facts (10)
SpecOpt is defined as a molecular design task: performing constrained structural modifications to existing compounds to make them preferentially bind to an intended target over known off-target proteins, while retaining their original structural characteristics and drug-like properties.
50%UnverifiedThe SpecOpt framework focuses on improving existing well-characterized drugs rather than generating entirely new selective molecules.
50%UnverifiedThe researchers constructed a benchmark for evaluating specificity optimization tasks based on compound-target interaction data from ChEMBL, in which intended targets are identified through drug mechanism annotations and off-target proteins are determined through measured activity data.
50%UnverifiedSpecOpt provides differential interaction information to a large language model, which then proposes targeted structural modification suggestions.
50%UnverifiedCandidate molecules generated by SpecOpt are accepted only if they simultaneously satisfy three criteria: molecular similarity, ADMET properties, and target-versus-off-target docking selectivity.
50%UnverifiedOn a test set of 915 compounds, SpecOpt improved the target-off-target binding gap for 84.8% of the compounds.
50%UnverifiedSpecOpt improved the average binding gap from -0.72 kcal/mol to +0.47 kcal/mol.
50%UnverifiedThe average Tanimoto similarity between SpecOpt-optimized molecules and their starting compounds was maintained at 0.72.
50%UnverifiedIn ablation experiments, when specific residue identities were replaced with binary contact indicators, the improvement effects completely disappeared for all 29 ablation compounds.
50%UnverifiedAblation studies indicate that residue-specific contact information is the key signal driving specificity optimization performance, and merely knowing that contacts exist is insufficient for making meaningful structural judgments.
50%